Profil de l'entreprise

Vous venez de lire:

SIR-Spheres® Y-90 Resin Microspheres Showed No Significant Difference in Overall Survival (OS) Compared to Sorafenib in Advanced HCC with Significantly Fewer Severe Adverse Events, New Asia-Pacific Study Finds

Nouvelles fournies par

Sirtex Medical Limited

Jun 05, 2017, 10:15 ET